Can we improve on nature? 'Super molecules' of factor VIII

Haemophilia

Volumn 4, Issue 4, 1998, Pages 370-379

  Kaufman, R J ^a   Pipe, S W ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Activated protein C; Factor VIII; Inhibitor antibodies; Thrombin

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANTIBODY PRODUCTION; BIOCHEMISTRY; CONFERENCE PAPER; GENE ISOLATION; GENETIC ENGINEERING; HEMOPHILIA A; PERIPHERAL VEIN; PRIORITY JOURNAL; PROTEIN STRUCTURE; SUBSTITUTION THERAPY; VASCULAR ACCESS;

EID: 0031876273     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1998.440370.x     Document Type: Conference Paper

References (96)

1. Patek AJ, Taylor FHL. Hemophilia II. Some properties of a substance obtained from normal human plasma effective in accelerating the coagulation of hemophilic blood. J Clin Invest 1937; 16: 113-24.
2. Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature 1984; 312: 337-42.
3. Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-7.
4. Jenny RJ, Pittman DD, Toole JJ, et al. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci USA 1987; 84: 4846-50.
5. Kane WH, Davie EW. Cloning of a cDNA coding for human factor V, a blood coagulation factor homologous to factor VIII andceruloplasmin. Proc Natl Acad Sci USA 1986; 83(18): 6800-4.
6. Ortel TL, Takahashi N, Putnam FW. Structural model of human ceruloplasmin based on internal triplication, hydrophilic/hydrophobic character, and secondary structure of domains. Proc Natl Acad Sci USA 1984; 81: 4761-5.
7. Stubbs JD, Lekutis C, Singer KL, et al. cDNA cloning of a mouse mammary epithelial cell surface protein reveals the existence of epidermal growth factor-like domains linked to factor VIII-like sequences. Proc Natl Acad Sci USA 1990; 87: 8417-21.
8. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature 1984; 312: 326-30.
9. Cripe LD, Moore KD, Kane WH. Structure of the gene for human coagulation factor V. Biochemistry 1992; 31: 3777-85.
10. Rosendaal FR, Varekamp I, Smit C, et al. Mortality and causes of death in Dutch haemophiliacs, 1973-86. Br J Haematol 1989; 71: 71-6.
11. Kamphuisen PW, Eikenboom JCJ, Vos HL, Blann AD, Bertina RM, Rosendaal FR. High levels of factor VIII antigen are an important risk factor of deep-vein thrombosis. Blood 1997; 90: 398a.
12. Lollar P, Parker CG. Stoichiometry of the porcine factor VIII-von Willebrand factor association. J Biol Chem 1987; 262: 17572-6.
13. Zucker MB, Soberano ME, Johnson AJ, Fulton AJ, Kowalski S, Adler M. The in vitro association of antihemophilic factor and von Willebrand factor. Thromb Haemost 1983; 49: 37-41.
14. Nesheim ME, Pittman DD, Wang JH, Slonosky D, Kaufman RJ. The binding of 35S-labeled recombinant factor VIII to activated and unactivated human platelets. J Biol Chem 1988; 263: 16467-70.
15. Hamer RJ, Koedam JA, Beeser-Visser NH, Bertina RM, van Mourik JA, Sixma JJ. Factor VIII binds to von Willebrand factor via its Mr-80,000 light chain. Eur J Biochem 1987; 166: 37-43.
16. Leyte A, Verbeet MP, Brodniewicz-Proba T, van Mourik JA, Mertens K. The interaction between human blood-coagulation factor VIII and von Willebrand factor. Characterization of a high-affinity binding site on factor VIII. Biochem J 1989; 257: 679-83.
17. Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on post-transfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest 1977; 60: 390-404.
18. Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood 1992; 79: 3130-7.
19. Tuddenham EG, Lane RS, Rotblat F, et al. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease. Br J Haematol 1982; 52: 259-67.
20. Douglas AS. Antihemophilic globulin assay following plasma infusion in hemophilia. J Lab Clin Med 1958; 51: 850-9.
21. Over J, Sixma JJ, Bruine MH, et al. Survival of 125 iodine-labeled factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human factor VIII. J Clin Invest 1978; 62: 223-34.
22. Brinkhous KM, Sandberg H, Garris JB, et al. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci USA 1985; 82: 8752-6.
23. Koedam JA. Interaction between factor VIII. Thesis. The University of Utrecht, The Netherlands, 1989.
24. Hamer RJ, Koedam JA, Beeser-Visser NH, Sixma JJ. The effect of thrombin on the. complex between factor VIII and von Willebrand factor. Eur J Biochem 1987; 167: 253-9.
25. Pittman DD, Alderman EA, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ. Biochemical, immunological, and in vivo functional characterization of B-domain deleted factor VIII. Blood 1993; 81: 2925-35.
26. Koedam JA, Meijers JC, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 1988; 82(4): 1236-43.
27. Fay PJ, Coumans JV, Walker FJ. von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J Biol Chem 1991; 266(4): 2172-7.
28. Andersson L-O, Brown JE. Interaction of factor VIII-von Willebrand factor with phospholipid vesicles. Biochem J 1981; 200: 161-7.
29. Lajmonovich A, Hudry-Clergeon G, Freyssinet J-M, Marguerie G. Human Factor VIII procoagulant activity and phospholipid interaction. Biochim Biophys Acta 1981; 678: 123-36.
30. Kaufman RJ, Wasley LC, Dorner AJ. Synthesis processing and secretion of factor VIII expressed in mammalian cells. J Biol Chem 1988; 263: 6352-62.
31. Kaufman RJ, Wasley LC, Davies MV, Wise RJ, Israel DI. The effect of von Willebrand factor co-expression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol Cell Biol 1989; 9:1233-42.
32. Wise RJ, Dorner AJ, Krane M, Pittman DD, Kaufman RJ. The role of von Willebrand factor multimerization and propeptide cleavage in the binding and stabilization of factor VIII. J Biol Chem 1991; 266: 21948-55.
33. Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. An immunogenic region with amino acid residues Va11670-Glu1684 of the factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor. J Biol Chem 1988; 263: 5230-4.
34. Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 1988; 263: 10451-5.
35. Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 1994; 269: 11601-5.
36. Saenko EL, Scandella D. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor. J Biol Chem 1997; 272: 18007-14.
37. Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS. A major factor VIII binding domain resides within the amino terminal 272 amino acid residues of von Willebrand factor. J Biol Chem 1987; 262: 8443-6.
38. Bahou WH, Ginsburg D, Sikkink R, Litwiller R, Fass DN. A monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding. J Clin Invest 1989; 84: 56-61.
39. Takahashi Y, Kalafatis M, Girma JP, Sewerin K, Andersson LO, Meyer D. Localization of a factor VIII binding domain on a 34 kilodalton fragment of the N-terminal portion of von Willebrand factor. Blood 1987; 70: 1679-82.
40. Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Coorelation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25(2): 505-12.
41. Fay PJ, Anderson MT, Chavin SI, Marder VJ. The size of human factor VIII heterodimers and the effects produced by thrombin. Biochim Biophys Acta 1986; 871: 268-78.
42. Fulcher CA, Roberts JR, Zimmerman TS. Thrombin proteolysis of purified factor VIII procoagulant protein: Correlation of activation with generation of a specific polypeptide. Blood 1983; 61: 807-11.
43. Lollar P, Parker CG. Subunit structure of thrombin-activated porcine factor VIII. Biochemistry 1987; 28: 666-74.
44. Fay PJ, Haidaris PJ, Smudzin TM. Human factor VIIIa subunit structure. J Biol Chem 1991; 266: 8957-62.
45. Pittman DD, Millenssen M, Bauer K, Kaufman RJ. The A2 domain of human recombinant derived factor VIII is required for procoagulant activity but not for thrombin cleavage. Blood 1991; 79: 389-97.
46. Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS. Proteolytic inactivation of human factor VIII procoagulant protein by activated protien C and its analogy with factor V. Blood 1984; 63: 486-9.
47. Fay PJ, Smudzin TM, Walker FJ. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem 1991; 266: 20139-45.
48. Griffin JH, Evatt B, Zimmerman TS, Kleiss A, Wideman C. Deficiency of protein C in congenital thrombolic disease. J Clin Invest 1981; 68: 1370-3.
49. Bertina RM, Broekmans AW, van der Linden IK, Mertens K. Protein C deficiency in a Dutch family with thrombolic disease. Thromb Haemost 1982; 48: 1-5.
50. Hultin MB, Jesty J. The activation and inactivation of human factor VIII by thrombin: effect of inhibitors of thrombin. Blood 1981; 57: 476-82.
51. Lollar P, Knutson GJ, Fass DN. Stabilization of thrombin-activated porcine factor VIII: C by factor IXa and phospholipid. Blood 1984; 63: 1303-8.
52. Lollar P, Parker CG. pH-dependent denaturation of thrombin-activated porcne factor VIII. J Biol Chem 1990; 265(3): 1688-92.
53. Lollar P, Parker CG. Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog. J Biol Chem 1991; 265(3): 12481-6.
54. Webster WP, Zukoski CF, Hutchin P, Reddick RL, Mandel SR, Penick GD. Plasma factor VIII synthesis and control as revealed by canine organ transplantation. Am J Physiol 1971; 220: 1147-54.
55. Lewis JH, Bontempo FA, Spero JA, Ragni MV, Starzl TE. Liver transplantation in a hemophiliac. N Engl J Med 1985; 312(18): 1189-90.
56. Kelly DA, Summerfield JA, Tuddenham EG. Localization of factor VIIIC: antigen in guinea-pig tissues and isolated liver cell fractions. Br J Haemalol 1984; 56: 535-43.
57. Zelechowska MG, van Mourik JA, Brodniewicz-Proba T. Ultrastructural localization of factor VIII procoagulant antigen in human liver hepatocytes. Nature 1985; 317: 729-30.
58. Wion KL, Kelly D, Summerfield JA, Tuddenham EGD, Lawn RM. Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 1985; 317: 726-9.
59. Kaufman RJ. Developing rDNA products for treatment of hemophilia A. Trends in Biotechnology 1991; 9: 353-9.
60. Toole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman RJ. A large region (≃95 kDA) of human factor VIII is dispensable for in vitro activity. Proc Natl Acad Sci USA 1986; 83: 5939-42.
61. Berntorp E. Second generation, B-domain deleted recombinant factor VIII. Thromb Haemost 1997; 78: 256-60.
62. Sela M, White Jr. FH, Anfinsen CB. Reductive cleavage of disulfide bridges in ribonuclease. Science 1957; 125: 691-3.
63. Munro S, Pelham HRB. An Hsp 70-like protein in the ER: Identity with the 78 Kd glucose-regulated protein and immunoglobulin heavy chain binding protein. Cell 1986; 46: 291-300.
64. Dorner AJ, Bole DG, Kaufman RJ. The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins. J Cell Biol 1987; 105: 2665-74.
65. Dorner AJ, Wasley LC, Kaufman RJ. Overexpression of GRP78 mitigates stress induction of glucose regulated proteins and blocks secretion of selective proteins in Chinese hamster ovary cells. EMBO J 1992; 11: 1563-71.
66. Flynn GC, Chappell TG, Rothman JE. Peptide binding and release by proteins implicated as catalysts of protein assembly. Science 1989; 245: 385-90.
67. Kozutsumi Y, Segal M, Normington K, Gething MJ, Sambrook J. The presence of malforded proteins in the endoplasmic reticulum signals the induction of glucose-regulated proteins. Nature 1988; 332: 462-4.
68. Lee AS. Mammalian stress response: Induction of the glucose-regulated protein family. Curr Opin Cell Biol 1992; 4: 267-73.
69. Dorner AJ, Wasley LC, Kaufman RJ. Protein dissociation from GRP78 and secretion is blocked by depletion of cellular ATP levels. Proc Natl Acad Sci USA 1990; 87: 7429-32.
70. Pittman DD, Tomkinson KN, Kaufman RJ. Post-translational requirements for functional factor V and factor VIII secretion in mammalian cells. J Biol Chem 1994; 269: 17329-37.
71. Marquette KA, Pittman DD, Kaufman RJ. A 110 amino acid region within the A1-domain of coagulation factor VIII inhibits secretion from mammalian cells. J Biol Chem 1995; 270(10): 10297-303.
72. Swaroop M, Moussalli M, Pipe SW, Kaufman RJ. Mutagenesis of a potential BiP binding site enhances secretion of coagulation factor VIII. J Biol Chem 1997; 272(39): 24121-4.
73. Inada Y, Matsushima A, Hiroto M, Nishimura H, Kodera Y. Modification of proteins with polyethylene glycol derivatives. Methods in Enzymology 1994; 242: 65-90.
74. Hershfield MS. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin Immun Immunopathol 1995; 76: S228-32.
75. Scandella D, DeGraaf Mahoney S, Mattingly M, Roeder D, Timmons L, Fulcher CA. Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli [published erratum appears in Proc Natl Acad Sci USA 1989 Feb; 86(4): 1387]. Proc Natl Acad Sci USA 1988; 85: 6152-6.
76. Scandella D, Mattingly M, de Graaf S, Fulcher CA. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood 1989; 74: 1618-26.
77. Fulcher CA, de Graaf Mahoney S, Roberts JR, Kasper CK, Zimmerman TS. Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments. Proc Natl Acad Sci USA 1985; 82: 7728-32.
78. Zhong D, Scandella D. Epitope of a hemophilia A inhibitor antibody overlaps the factor VIII binding site for factor IX. Blood 1996; 88: 324a.
79. Gilles JG, Arnout J, Vermylen J, Saint-Remy JM. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 1993; 82: 2452-61.
80. Hay C, Lozier JN. Porcine factor VIII therapy in patients with factor VIII inhibitors. [Review] [11 refs]. Adv Experimental Med Biol 1995; 386: 143-51.
81. Kernoff PBA. Porcine factor VIII: preparation and use in treatment of inhibitor patients. In: Factor VIII Inhibitors. Hoyer LW, ed. New York: Alan R. Liss, 1984; 207-24.
82. Healey JF, Lubin IM, Nakai H, et al. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem 1995; 270: 14505-9.
83. Lubin IM, Healey JF, Barrow RT, Scandella D, Lollar P. Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis. J Biol Chem 1997; 272: 30191-5.
84. Pittman DD, Kaufman RJ. The proteolytic requirements for activation and inactivation of antihemophilic factor (Factor VIII). Proc Natl Acad Sci USA 1988; 85: 2429-33.
85. Hill-Eubanks DC, Parker CG, Lollar P. Differential proteolytic activation of factor VIII - von Willebrand factor complex by thrombin. Proc Natl Acad Sci USA 1989; 86: 6508-12.
86. Pipe SW, Kaufman RJ. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci USA 1997; 94: 11851-6.
87. Amano K, Michnick DA, Moussalli M, Kaufman RJ. Mutation at either Arg336 or Arg562 in Factor VIII is insufficient for complete resistance to activated protein C (APC)-mediated inactivation: Implications for the APC resistance test. Thromb Haemost, in press.
88. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH,Jr.. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A [letter]. Nat Genet 1995; 10: 119-21.
89. Giles AR, Tinlin S, Greenwood R. A canine model of hemophilic (factor VIII: C deficiency) bleeding. Blood 1982; 60: 727-30.
90. Zaitseva I, Zaitsev V, Card G, et al. The x-ray structure of human serum ceruloplasmin at 3.1: nature of the copper centres. J Biol Inorg Chem 1996; 1: 15-23.
91. Pemberton S, Lindley P, Zaitsev V, Card G, Tuddenham EGD, Kemball-Cook G. A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood 1997; 89: 2413-21.
92. Fay PJ, Beattie T, Huggins CF, Regan LM. Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site. J Biol Chem 1994; 269(12): 20522-7.
93. O'Brien LM, Medved LV, Fay PJ. Localization of factor IXa and factor Villa interactive sites. J Biol Chem 1995; 270: 27087-92.
94. Lenting PJ, Christophe OD, Maat H, Rees DJG, Mertens K. Ca2+ binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding. J Biol Chem 1996; 271: 25332-7.
95. Lenting PJ, van de Loo JW, Donath MJ, van Mourik JA, Mertens K. The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX. J Biol Chem 1996; 271: 1935-40.
96. Bode W, Brandstetter H, Mather T, Stubbs MT. Comparative analysis of haemostatic proteinases: structural aspects of thrombin, factor Xa, factor IXa and protein C. Thromb Haemost 1997; 78: 501-11.